Who are Comirnaty Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b2 (Omi XBB.1.5), BNT162b5 Bivalent (WT/OMI BA.2), mRNA-1273 vaccine, mRNA-1283, mRNA-1273.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comirnaty-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Comirnaty Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comirnaty Vaccine (Comirnaty Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

phase 3 mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Comirnaty Vaccine (Comirnaty Vaccine) — Clover Biopharmaceuticals AUS Pty. Comirnaty is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Comirnaty Vaccine TARGET	Comirnaty Vaccine	Clover Biopharmaceuticals AUS Pty	phase 3	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BNT162b7 Bivalent (Original/OMI BA.4/BA.5)	bnt162b7-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 (Omi XBB.1.5)	bnt162b2-omi-xbb-1-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b5 Bivalent (WT/OMI BA.2)	bnt162b5-bivalent-wt-omi-ba-2	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273 vaccine	mRNA-1273 vaccine	University Health Network, Toronto	marketed	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1283	mRNA-1283	ModernaTX, Inc.	marketed	mRNA vaccine	HPV16 and HPV18 antigens (E6 and E7 proteins)
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comirnaty Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/comirnaty-vaccine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing